In vitro and in vivo evaluations of the antibiotic efrotomycin

Experiments were conducted to determine the potential of the antibiotic efrotomycin as a growth permittant for poultry and to further elucidate the mode of action of antimicrobial agents for that purpose. Efrotomycin as the semipurified antibiotic and as fermentation solids demonstrated excellent activity against Clostridium perfringens at .1 to .2 ppm based on suppression of gas production in an anaerobic tube test. Supplementing a soybean protein and sucrose-based diet with levels of 2.2, 11, and 55 ppm of the antibiotic, from the two sources each with two different purities, improved weight gain of chicks an average of 23% and improved feed efficiency an average of 13% at the higher levels (all P less than .01). Computed indexes for each antibiotic treatment, which represent the combined effects of both weight gain and feed efficiency, showed that a maximum response was generally obtained at the 11 ppm level and that the antibiotic as fermentation solids was slightly more active than the semipurified material. Supplementing the soybean protein and sucrose-based diet with levels of 1.1, 5.5, 16.5, and 55 ppm of efrotomycin reduced the numbers of C. perfringens organisms in ileal contents of chicks (all P less than .01). The effects were dose-related. Control chicks in this experiment averaged greater than 7.7 log10 of C. perfringens counts per gram of contents. The results of these experiments show that efrotomycin has excellent growth-permittant activity and the activity correlates with the antibacterial activity against C. perfringens.